Dr. Agarwal's Health Care Intrinsic Value
Dr. Agarwal's Health Care (AGARWALEYE) median intrinsic value is ₹578.00 from 9 valuation models (range ₹150–₹1251), vs current price ₹500.45 — +15.5% upside (Trading Below Median Value), margin of safety 13.4%. For current market price and key ratios, visit AGARWALEYE stock price BSE.
AGARWALEYE Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Agarwal's Health Care intrinsic value across 9 models vs current price ₹500.45 — upside/downside and value range per method. Check AGARWALEYE company valuation to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹150.13 | ₹120.10 - ₹180.16 | -70.0% | EPS: ₹5.00, Sector P/E: 12x |
| Book Value Method | asset | ₹633.12 | ₹569.81 - ₹696.43 | +26.5% | Book Value/Share: ₹633.12, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹578.00 | ₹520.20 - ₹635.80 | +15.5% | Revenue/Share: ₹722.50, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1000.90 | ₹900.81 - ₹1100.99 | +100.0% | EBITDA: ₹700.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1251.12 | ₹1000.90 - ₹1501.34 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹150.13 | ₹135.12 - ₹165.14 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹150.13 | ₹135.12 - ₹165.14 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹625.00 | ₹562.50 - ₹687.50 | +24.9% | ROE: 9.9%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹266.88 | ₹240.19 - ₹293.57 | -46.7% | EPS: ₹5.00, BVPS: ₹633.12 |
AGARWALEYE Intrinsic Value vs Market Price — All Valuation Models
Dr. Agarwal's Health Care fair value range ₹150–₹1251 vs current market price ₹500.45 across 9 valuation models. See Dr. Agarwal's Health Care P/B ratio trends to compare market price against book value per share.
AGARWALEYE Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Agarwal's Health Care median intrinsic value ₹578.00, current price ₹500.45 — Trading Below Median Value by 15.5%, margin of safety 13.4%.
What is the intrinsic value of AGARWALEYE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Dr. Agarwal's Health Care (AGARWALEYE) is ₹578.00 (median value). With the current market price of ₹500.45, this represents a +15.5% variance from our estimated fair value.
The valuation range spans from ₹150.13 to ₹1251.12, indicating ₹150.13 - ₹1251.12.
Is AGARWALEYE undervalued or overvalued?
Based on our multi-method analysis, Dr. Agarwal's Health Care (AGARWALEYE) appears to be trading below median value by approximately 15.5%.
AGARWALEYE Financial Health — Key Ratios vs Industry Benchmarks
Dr. Agarwal's Health Care financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.42 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 9.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 29.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AGARWALEYE Cash Flow Quality — Operating & Free Cash Flow
Dr. Agarwal's Health Care operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹360 Cr | ₹-15 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹346 Cr | ₹-111 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹233 Cr | ₹-22 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹164 Cr | ₹87 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹99 Cr | ₹76 Cr | Positive Free Cash Flow | 8/10 |